Literature DB >> 19772943

Oral chronic graft-versus-host disease scoring using the NIH consensus criteria.

Nathaniel S Treister1, Kristen Stevenson, Haesook Kim, Sook-Bin Woo, Robert Soiffer, Corey Cutler.   

Abstract

The National Institutes of Health (NIH) Oral chronic Graft-versus-Host Disease (cGVHD) Activity Assessment Instrument is intended to be simple to use and to provide a reproducible objective measure of disease activity over time. The objective of this study was to assess inter- and intraobserver variability in the component and composite scores in patients evaluated with oral cGVHD. Twenty-four clinicians (bone marrow transplant [BMT] oncologists: BMTE, n = 16; BMT midlevel providers: BMT MLP; n = 4; and oral medicine experts [OME], n = 4), from 6 major transplant centers scored high-quality intraoral photographs of 12 patients. The same photographs were evaluated 1 week later by the same evaluators. An intraclass correlation coefficient (ICC) was used to calculate intrarater reliability and interrater agreement was analyzed using a weighted kappa statistic: 0 <or= kappa <or= 0.20 = poor, 0.21 <or= kappa <or= 0.40 = fair, 0.41 <or= kappa <or= 0.60 = moderate, 0.61 <or= kappa <or= 0.80 = good, 0.81 <or= kappa <or= 1.00 = very good. Data on participant experiences and demographics were also collected. Mean interrater reliability for each element was poor to moderate (range: 0.15-0.46). Overall mean kappa scores were highest for ulcers (0.46), followed by erythema (0.23), and lowest for lichenoid (0.15) and mucoceles (0.14). Kappa scores were higher in OME compared with BMTE and BMT MLP in ulcers and erythema (eg, 0.85, 0.44, 0.33 for ulcers, respectively), but similar in lichenoid and mucoceles. Overall intrarater reliability in all groups was very good (>or=0.90) and highest for ulcers (0.97, 0.85, 0.94). Although 75% of OME were comfortable with their abilities to score the cases, approximately 50% of BMTE and BMT MLP were uncomfortable. The majority felt that their evaluations were accurate; however, 84% agreed that formal training is required. Interrater variability of the oral cGVHD instrument is unacceptable for the purposes of clinical trials. Greater concordance among OME, high intrarater reliability, and participant feedback suggests that formal training may significantly decrease variability. Parallel investigations must be completed using the other organ specific instruments prior to any revision and widespread prospective utilization of these tools as research endpoints. Copyright (c) 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19772943     DOI: 10.1016/j.bbmt.2009.09.010

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  10 in total

1.  Oral chronic graft-versus-host disease: report from the International Consensus Conference on clinical practice in cGVHD.

Authors:  Johannes K-H Meier; Daniel Wolff; Steve Pavletic; Hildegard Greinix; Martin Gosau; Hartmut Bertz; Stefanie J Lee; Anita Lawitschka; Sharon Elad
Journal:  Clin Oral Investig       Date:  2010-09-22       Impact factor: 3.573

2.  Validation of the National Institutes of Health chronic GVHD Oral Mucosal Score using component-specific measures.

Authors:  C W Bassim; H Fassil; J W Mays; D Edwards; K Baird; S M Steinberg; K M Williams; E W Cowen; S A Mitchell; K Cole; T Taylor; D Avila; D Zhang; D Pulanic; L Grkovic; D Fowler; R E Gress; S Z Pavletic
Journal:  Bone Marrow Transplant       Date:  2013-09-02       Impact factor: 5.483

Review 3.  Oral Complications of Chronic Graft-Versus-Host Disease.

Authors:  Jane M Fall-Dickson; Steven Z Pavletic; Jacqueline W Mays; Mark M Schubert
Journal:  J Natl Cancer Inst Monogr       Date:  2019-08-01

4.  Clinical approach in the management of oral chronic graft-versus-host disease (cGVHD) in a series of specialized medical centers.

Authors:  Sharon Elad; Siri Beier Jensen; Judith E Raber-Durlacher; Nancy Mouradian; Elvira M P Correa; Mark M Schubert; Nicole M A Blijlevens; Joel B Epstein; Deborah P Saunders; Tuomas Waltimo; Noam Yarom; Yehuda Zadik; Michael T Brennan
Journal:  Support Care Cancer       Date:  2014-11-23       Impact factor: 3.603

5.  A multicenter pilot evaluation of the National Institutes of Health chronic graft-versus-host disease (cGVHD) therapeutic response measures: feasibility, interrater reliability, and minimum detectable change.

Authors:  Sandra A Mitchell; David Jacobsohn; Kimberly E Thormann Powers; Paul A Carpenter; Mary E D Flowers; Edward W Cowen; Mark Schubert; Maria L Turner; Stephanie J Lee; Paul Martin; Michael R Bishop; Kristin Baird; Javier Bolaños-Meade; Kevin Boyd; Jane M Fall-Dickson; Lynn H Gerber; Jean-Pierre Guadagnini; Matin Imanguli; Michael C Krumlauf; Leslie Lawley; Li Li; Bryce B Reeve; Janine Austin Clayton; Georgia B Vogelsang; Steven Z Pavletic
Journal:  Biol Blood Marrow Transplant       Date:  2011-04-12       Impact factor: 5.742

6.  Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report.

Authors:  Stephanie J Lee; Daniel Wolff; Carrie Kitko; John Koreth; Yoshihiro Inamoto; Madan Jagasia; Joseph Pidala; Attilio Olivieri; Paul J Martin; Donna Przepiorka; Iskra Pusic; Fiona Dignan; Sandra A Mitchell; Anita Lawitschka; David Jacobsohn; Anne M Hall; Mary E D Flowers; Kirk R Schultz; Georgia Vogelsang; Steven Pavletic
Journal:  Biol Blood Marrow Transplant       Date:  2015-03-19       Impact factor: 5.742

Review 7.  Oral Chronic Graft-Versus-Host Disease.

Authors:  David Dean; Herve Sroussi
Journal:  Front Oral Health       Date:  2022-05-20

Review 8.  Classification systems for chronic graft-versus-host disease.

Authors:  Stephanie J Lee
Journal:  Blood       Date:  2016-11-07       Impact factor: 22.113

9.  Measurement of oral chronic GVHD: results from the Chronic GVHD Consortium.

Authors:  N Treister; X Chai; B Kurland; S Pavletic; D Weisdorf; J Pidala; J Palmer; P Martin; Y Inamoto; M Arora; M Flowers; D Jacobsohn; M Jagasia; S Arai; S J Lee; C Cutler
Journal:  Bone Marrow Transplant       Date:  2013-01-28       Impact factor: 5.483

10.  Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria.

Authors:  Geoffrey D E Cuvelier; Eneida R Nemecek; Justin T Wahlstrom; Carrie L Kitko; Victor A Lewis; Tal Schechter; David A Jacobsohn; Andrew C Harris; Michael A Pulsipher; Henrique Bittencourt; Sung Won Choi; Emi H Caywood; Kimberly A Kasow; Monica Bhatia; Benjamin R Oshrine; Allyson Flower; Sonali Chaudhury; Donald Coulter; Joseph H Chewning; Michael Joyce; Süreyya Savaşan; Anna B Pawlowska; Gail C Megason; David Mitchell; Alexandra C Cheerva; Anita Lawitschka; Lori J West; Bo Pan; Yazid N Al Hamarneh; Anat Halevy; Kirk R Schultz
Journal:  Blood       Date:  2019-05-01       Impact factor: 25.476

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.